Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2023
Reply to R. Sun et al
Jacobus Pfisterer, Joern Rau
Journal of Neurosurgery
|
April 6, 2019
Comparing two randomized deep brain stimulation trials for Parkinson's disease
Günther Deuschl, Kenneth A Follett, Ping Luo, et al.
Plos One
|
August 22, 2020
Interpretation of health-related quality of life outcomes in Parkinson's disease from the EARLYSTIM Study
Pablo Martinez-Martin, Guenther Deuschl, Lisa Tonder, et al.
Movement Disorders Clinical Practice
|
August 11, 2020
Deep Brain Stimulation Impact on Social and Occupational Functioning in Parkinson's Disease with Early Motor Complications
Valerie Stoker, Paul Krack, Lisa Tonder, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2016
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial
Antonio González-Martín, Patricia Pautier, Sven Mahner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 18, 2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
Domenica Lorusso, Felix Hilpert, Antonio González Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 3, 2022
The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life
Inken Tödt, Bassam Al-Fatly, Oliver Granert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2023
Reply to R. Sun et al
Jacobus Pfisterer, Joern Rau
Journal of Neurosurgery
|
April 6, 2019
Comparing two randomized deep brain stimulation trials for Parkinson's disease
Günther Deuschl, Kenneth A Follett, Ping Luo, et al.
Plos One
|
August 22, 2020
Interpretation of health-related quality of life outcomes in Parkinson's disease from the EARLYSTIM Study
Pablo Martinez-Martin, Guenther Deuschl, Lisa Tonder, et al.
Movement Disorders Clinical Practice
|
August 11, 2020
Deep Brain Stimulation Impact on Social and Occupational Functioning in Parkinson's Disease with Early Motor Complications
Valerie Stoker, Paul Krack, Lisa Tonder, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2016
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial
Antonio González-Martín, Patricia Pautier, Sven Mahner, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 18, 2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
Domenica Lorusso, Felix Hilpert, Antonio González Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 3, 2022
The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life
Inken Tödt, Bassam Al-Fatly, Oliver Granert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Page
of 2